Proteomic analysis with key proteins functional validation study of cerebrospinal fluid in primary central nervous system lymphoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200066526

Enrollment

Unknown

Registered

2022-12-07

Start date

2022-12-15

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma (PCNSL)

Interventions

PCNSL group:None

Control group1:None

Control group 2:None

PCNSL group with good prognosis:None

PCNSL group with poor prognosis:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnostic research: (1) Experimental group: 1) Aged between 18 and 75 years, no gender limit; 2) Primary central nervous system lymphoma was confirmed by clinicopathology, and the remaining cerebrospinal fluid and brain tissue samples were collected after routine clinical diagnosis and treatment before treatment; 3) Follow-up treatment in our hospital or other hospitals, complete clinical data and information, always available for contact and follow-up. (2) Control group: 1) Aged between 18 and 75 years, no gender limit; 2) Clinically confirmed benign diseases of the central nervous system (optional include almost normal people, brain trauma, benign tumors, autoimmune encephalopathy, viral encephalitis, etc.) and other malignant tumors of the central nervous system (including brain metastases, glioma, etc.); 3) Residual cerebrospinal fluid samples collected and tested after clinical routine treatment before treatment. 2. Prognostic study: (1) Aged between 18 and 75 years, no gender limit; (2) Primary central nervous system lymphoma was diagnosed, and the remaining cerebrospinal fluid and brain tissue samples were routinely collected and detected before treatment; (3) Follow-up treatment in our hospital or other hospitals, complete clinical data and information, always available for contact and follow-up.

Exclusion criteria

Exclusion criteria: CSF samples are not sufficient for laboratory testing or for those deemed unsuitable by the investigator.

Design outcomes

Primary

Measure	Time frame
Eastern Cooperative Oncology Group Score;Blood routine;Cerebrospinal fluid routine;Cerebrospinal fluid protein;Cytology of cerebrospinal fluid;	—

Countries

China

Contacts

Public ContactChen Bobin

Huashan Hospital, Fudan University

bbchen@fudan.edu.cn+86 13402186236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026